Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
Facilitates well-planned cancer prevention and control clinical trials by addressing information gaps to improve trial design and feasibility, saving time and money for NCI.
Browse similar grants
Funder: National Institutes of Health
Due Dates: February 25, 2027 (Application) | June 25, 2027 (Application) | October 25, 2027 (Application)
Funding Amounts: Up to $225,000 annually in direct costs; three-year totals capped at $450,000 without a clinical trial or $600,000 with a pilot/feasibility trial
Summary: Supports preparatory studies needed to finalize feasible, rigorous multicenter cancer prevention and control clinical trials.
Key Information: Preliminary efficacy or effectiveness data supporting the future intervention trial must already exist when applying.
Description
The National Cancer Institute (NCI) administers this U34 planning cooperative agreement to obtain data critical to completing the protocol for a future full-scale, multicenter Phase II or later-phase trial. Supported work spans cancer prevention and interception, screening, early detection, health behaviors, healthcare delivery, survivorship, supportive and palliative care, symptom management, implementation science, and quality of life.
Planning studies should resolve specific uncertainties about populations, recruitment, interventions, endpoints, statistical design, or operational feasibility. Activities may include refining instruments, standardizing interventions across sites, testing adherence or acceptability, and identifying comparison groups. A pilot/feasibility clinical trial is optional and should be included only when essential. The program is not intended to establish the initial efficacy rationale for a future trial, but to provide information necessary for final decisions about its design and conduct.
